Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.63 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.63 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25453172 | 0.84 | OPRL1 (0.65) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL24422204 | 0.84 | CYP2D6 (0.58) | OPRM1OPRL1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL8639468 | 0.83 | OPRL1 (0.56) | OPRM1OPRL1OPRD1OPRK1CCR3 | |
| SCHEMBL23901648 | 0.83 | OPRL1 (0.63) | OPRM1OPRL1OPRD1OPRK1CCR1 | |
| SCHEMBL10057646 | 0.83 | OPRM1 (0.63) | OPRM1OPRL1OPRD1OPRK1CCR1 | |
| SCHEMBL22005072 | 0.82 | OPRM1 (0.46) | OPRM1OPRL1OPRD1OPRK1CCR3 | |
| SCHEMBL7696081 | 0.82 | OPRL1 (0.73) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL10057684 | 0.82 | CYP2D6 (0.48) | OPRM1OPRL1OPRD1OPRK1CCR1 | |
| SCHEMBL23384021 | 0.81 | OPRM1 (0.67) | OPRM1OPRL1OPRD1OPRK1DRD2 | |
| SCHEMBL3591425 | 0.80 | CCR3 (0.57) | OPRM1OPRL1OPRD1OPRK1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9724321-B2 | Histone deacetylase inhibitors | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9199923-B2 | Histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150038581-A1 | HISTONE DEACETYLASE INHIBITORS | Harvard University & Medical School | 2015-02-05 | — | — | US | disclosed |
| US-20140213620-A1 | HISTONE DEACETYLASE INHIBITORS | BRADNER JAMES ELLIOT (US) | 2014-07-31 | — | — | US | disclosed |
| US-8754237-B2 | Bifunctional histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-17 | — | — | US | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| US-7511046-B2 | Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists | AVENTIS HOKLINGS INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| WO-2007095584-A2 | Histone Deacetylase Inhibitors | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-08-23 | — | — | WO | disclosed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | OPRM1 4093/4885OPRL1 2302/4885OPRD1 4219/4885 |
| US-20140213620-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | OPRM1 4883/4885OPRL1 4383/4885OPRD1 4699/4885 |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | OPRM1 4868/4885OPRL1 4092/4885OPRD1 4713/4885 |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | HDAC6, HDAC1, HDAC5 | OPRM1 4642/4885OPRL1 4253/4885OPRD1 4011/4885 |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | OPRM1 4883/4885OPRL1 4383/4885OPRD1 4699/4885 |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | DRD4, DRD2, SLC6A3 | OPRM1 87/4885OPRL1 35/4885OPRD1 18/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | OPRM1 4575/4885OPRL1 4581/4885OPRD1 4216/4885 |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | OPRM1 4147/4885OPRL1 4491/4885OPRD1 3897/4885 |
| US-20150038581-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | OPRM1 4883/4885OPRL1 4383/4885OPRD1 4699/4885 |
| US-20080269245-A1 | Dioxanes and uses thereof | UTS2R, MAN2B2, AMDHD2 | OPRM1 4544/4885OPRL1 4506/4885OPRD1 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.